Last reviewed · How we verify
Vitamin B12-ratiopharm N, injection solution
Vitamin B12-ratiopharm N, injection solution is a Small molecule drug developed by Swedish Orphan Biovitrum. It is currently in Phase 1 development.
Vitamin B12-ratiopharm N facilitates the metabolism of homocysteine and methylmalonyl-CoA by acting as a cofactor for methionine synthase and methylmalonyl-CoA mutase.
At a glance
| Generic name | Vitamin B12-ratiopharm N, injection solution |
|---|---|
| Sponsor | Swedish Orphan Biovitrum |
| Modality | Small molecule |
| Phase | Phase 1 |
Mechanism of action
This vitamin helps convert homocysteine to methionine and methylmalonyl-CoA to succinyl-CoA, essential processes for maintaining healthy nerve function and red blood cell formation.
Approved indications
Common side effects
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Vitamin B12-ratiopharm N, injection solution CI brief — competitive landscape report
- Vitamin B12-ratiopharm N, injection solution updates RSS · CI watch RSS
- Swedish Orphan Biovitrum portfolio CI